{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-211130","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2024-08-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.049339+00:00","generated_at":"2026-05-31T06:46:52.109071+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Fate Therapeutics adopts amended indemnification agreements for directors and officers","bullets":["Board approved amended form of indemnification agreement effective August 26, 2024.","Revised change-of-control definition and added coverage of separate counsel expenses in change of control.","Advancement of defense expenses clarified to be irrespective of insurance coverage.","Includes express presumption of good faith in favor of Indemnitee (burden on challenger).","Indemnitee may seek specific performance without showing irreparable harm."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-211130","json":"https://secwatch.observer/filing/0001193125-24-211130.json","markdown":"https://secwatch.observer/filing/0001193125-24-211130.md","text":"https://secwatch.observer/filing/0001193125-24-211130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312524211130/0001193125-24-211130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312524211130/d703760d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:46:52.109071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}